Clinical Trials

After a Successful Phase 1 that assessed the safety of a MAP4343 injection in healthy volunteers, MAPREG led a second phase 1 to assess the pharmacokinetics of a MAP4343 pill.

MAPREG is now launching Proof of Concept Phase 2 trials in Depressive Disorders (multicentric, France, support from DGOS) and in Alcohol Addiction (monocentric, USA, support from NIAAA), with MAP4343 oral treatment.

If you are a patient, a physician, a pharmaceutical company or an investor, please contact us to know more.

CHU Bicêtre, Batiment Pincus, 80 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France.